These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7919571)

  • 1. Antiulcer prescribing program in a state correctional system.
    Keith MR; Cason DM; Helling DK
    Ann Pharmacother; 1994 Jun; 28(6):792-6. PubMed ID: 7919571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group.
    Cook D; Guyatt G; Marshall J; Leasa D; Fuller H; Hall R; Peters S; Rutledge F; Griffith L; McLellan A; Wood G; Kirby A
    N Engl J Med; 1998 Mar; 338(12):791-7. PubMed ID: 9504939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulary designation of cimetidine as the primary intravenous histamine H2-receptor antagonist.
    Berkowitz HS
    Am J Hosp Pharm; 1992 Jan; 49(1):134-5. PubMed ID: 1349201
    [No Abstract]   [Full Text] [Related]  

  • 4. Rational selection of H2-receptor antagonists for the hospital formulary. Roundtable discussion.
    Keeffe EB; Harper JM; LeMay A; Sherrin TP; Siepler JK
    Hosp Formul; 1991 Nov; 26 Suppl D():13-9. PubMed ID: 10136560
    [No Abstract]   [Full Text] [Related]  

  • 5. Antiulcer therapy: an exercise in formulary management.
    Foulke GE; Siepler J
    J Clin Gastroenterol; 1990; 12 Suppl 2():S64-8. PubMed ID: 1978846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National survey of stress ulcer prophylaxis.
    Lam NP; Lê PD; Crawford SY; Patel S
    Crit Care Med; 1999 Jan; 27(1):98-103. PubMed ID: 9934901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical appropriateness, therapeutic equivalence, and cost of conversion of H2 antagonist therapy.
    Kitrenos JG; Brown DR; Letting DJ; Rotella DL
    Hosp Formul; 1993 Jan; 28(1):86-8, 91, 95-6. PubMed ID: 10123271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-use review program for concurrent histamine H2-receptor antagonist-sucralfate therapy.
    Kane MP; Briceland LL; Garris RE; Favreau BN
    Am J Hosp Pharm; 1990 Sep; 47(9):2007-10. PubMed ID: 1977317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiulcer drug prescribing in hospital successfully influenced by "immediate concurrent feedback".
    Kumana CR; Ching TY; Cheung E; Kong Y; Kou M; Chan CK; Chu KM; Seto WH; Lam SK
    Clin Pharmacol Ther; 1998 Nov; 64(5):569-74. PubMed ID: 9834050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
    Lucas LM; Gerrity MS; Anderson T
    Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shifting physician prescribing to a preferred histamine-2-receptor antagonist. Effects of a multifactorial intervention in a mixed-model health maintenance organization.
    Brufsky JW; Ross-Degnan D; Calabrese D; Gao X; Soumerai SB
    Med Care; 1998 Mar; 36(3):321-32. PubMed ID: 9520957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic-interchange program for oral histamine H2-receptor antagonists.
    Chase SL; Peterson AM; Wordell CJ
    Am J Health Syst Pharm; 1998 Jul; 55(13):1382-6. PubMed ID: 9659966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A comparative evaluation of the efficacy of sucralfate and H2-histamine blockaders in treating peptic ulcer].
    Ivashkin VT; Tkachenko EI; Grinevich VB; Sultanov VK; Inozemtsev SA
    Ter Arkh; 1989; 61(8):59-62. PubMed ID: 2573963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital.
    Coppola P
    Hosp Pharm; 1991 Feb; 26(2):126-9, 142. PubMed ID: 10136547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of histamine2-receptor blocking agents and sucralfate in a health maintenance organization following continued clinical pharmacist intervention.
    Mead RA; McGhan WF
    Drug Intell Clin Pharm; 1988 Jun; 22(6):466-9. PubMed ID: 2899491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in prescribing patterns of intravenous histamine2-receptor antagonists results in significant cost savings without adversely affecting patient care.
    Fudge KA; Moore KA; Schneider DN; Sherrin TP; Wellman GS
    Ann Pharmacother; 1993 Feb; 27(2):232-7. PubMed ID: 8094986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with a two-tiered therapeutic interchange policy.
    Rich DS
    Am J Hosp Pharm; 1989 Sep; 46(9):1792-8. PubMed ID: 2572167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic analysis of inadequate prescription of antiulcer medications for in-hospital patients at a third level institution in Colombia.
    Machado-Alba JE; Castrillón-Spitia JD; Londoño-Builes MJ; Fernández-Cardona A; Campo-Betancourth CF; Ochoa-Orozco SA; Echeverri-Cataño LF; Ruiz-Villa JO; Gaviria-Mendoza A
    Rev Esp Enferm Dig; 2014 Feb; 106(2):77-85. PubMed ID: 24852732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
    Segal R; Oh T; Ben-Joseph R; Russell WL
    Hosp Formul; 1994 May; 29(5):379-82, 388-91. PubMed ID: 10136601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidisciplinary education ensures successful formulary conversion.
    Barfield PS; Amerson AB
    Hosp Formul; 1991 Nov; 26 Suppl D():28-9. PubMed ID: 10136563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.